Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mediwound Ltd MDWD

Healthcare
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in... see more

Recent & Breaking News (NDAQ:MDWD)

BARDA Upsizes Support for NexoBrid with an Additional $21 Million to Fund Continuous Access Treatment Protocol for Thermal Burn

GlobeNewswire May 29, 2019

MediWound to Host First Quarter Financial Results Conference Call on May 21at 8:30 a.m. Eastern Time

GlobeNewswire May 14, 2019

MediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid® in North America

GlobeNewswire May 7, 2019

Mid-Morning Market Update: Markets Open Lower; Johnson & Johnson Profit Tops Expectations

Benzinga.com  January 22, 2019

24 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  January 22, 2019

A Peek Into The Markets: US Stock Futures Drop Ahead Of Earnings

Benzinga.com  January 22, 2019

MediWound Announces Positive Top-Line Results from Its Pivotal Phase 3 Study (DETECT) in NexoBrid® for Eschar Removal of Severe Thermal Burns

GlobeNewswire January 22, 2019

MediWound Reports Third Quarter 2018 Financial Results

GlobeNewswire November 13, 2018

MediWound to Host Third Quarter 2018 Financial Results Conference Call on November 13 at 8:30 a.m. Eastern Time

GlobeNewswire November 7, 2018

MediWound Awarded Additional BARDA Contract Valued Up to $43 Million for Development of NexoBrid® for Sulfur Mustard Injuries

GlobeNewswire September 24, 2018

NexoBrid® Receives Marketing Authorization from Russia's Ministry of Health

GlobeNewswire September 5, 2018

MediWound to Present at 13th Annual Wells Fargo Securities Healthcare Conference

GlobeNewswire September 4, 2018

MediWound Reports Second Quarter 2018 Financial Results

GlobeNewswire August 7, 2018

MediWound to Host Second Quarter 2018 Financial Results Conference Call on August 7 at 8:30 a.m. Eastern Time

GlobeNewswire July 31, 2018

MediWound Expands Its NexoBrid® Phase 3 Children Innovation Debridement Study (CIDS) to the U.S.

GlobeNewswire June 19, 2018

MediWound Completes Enrollment in NexoBrid® U.S. Phase 3 DETECT Study

GlobeNewswire June 11, 2018

NexoBrid® Receives Marketing Authorization From South Korea’s Ministry of Health

GlobeNewswire June 4, 2018

FDA Clears Development Pathway for NexoBrid® for Sulfur Mustard Injuries

GlobeNewswire May 29, 2018

MediWound Reports First Quarter 2018 Financial Results

GlobeNewswire May 10, 2018

MediWound to Host First Quarter 2018 Financial Results Conference Call on May 10 at 8:30 a.m. Eastern Time

GlobeNewswire May 4, 2018